Mario Adami

Acted as the Finance Business Partner for Global R&D and Corporate Function, supervising a budget of more than USD 500M and a finance team located across Europe Owned the strategic financial plan for R&D and Corporate Functions, ensuring the annual plan accurately reflected strategic priorities and approved investments. Partnered with portfolio management to maintain external spend outlook of USD 200M with a balanced financial risk and opportunity profile, leveraging best practices to optimize resource use

Acted as the Finance Business Partner for Global Neuroscience & Gastrointestinal Franchise, supervising a marketing budget of more than USD 300M and a finance team located in Switzerland/HQ. Led the MRP and MYC planning cycles for GPLS NS & GI, delivering franchise level insights on trajectory, long term financial risks, and operational priorities. Analyzed periodic franchise results, assessed variances vs. budget/forecast, and ensured transparent financial performance reporting.

Acted as Finance Business Partner for Global Ophthalmology, Genetic Disease & Neuroscience, supervising a marketing budget of more than USD 350M and a finance team. Guided all core financial planning cycles (annual budget, 3-year plan, 10-year long-range plan). Directed monthly financial performance analysis & reporting, working with brand teams on marketing strategies & optimize spend allocation. Enabled strategic pipeline decision-making incl. NPV/eNPV asset evaluations , KPI-driven resource reallocation

Led key supply chain initiatives, including transitioning Alcon Ophthalmic production from toll to contract manufacturing and harmonizing raw material ordering, purchasing, and invoicing processes within the global NTO organization.

Acted as the Finance Business Partner for Global Development Oncology program, supervising a global Oncology Development project budget of more than USD 100M and a finance team. Directed all financial processes for global Oncology Development projects spanning planning cycles, 5 year forecasts, variance analysis, and executive reporting with risk & opportunity recommendations. Guided key integration initiatives, incl. transitioning the Oncology TM portfolio into NIBR, integrating the GSK Onc. portfolio

Acted as the Finance Business Partner for Development Oncology Emerging Growth Markets, supervising a USD 12M Onc. Development and a finance team in China and South Korea. Drove significant productivity improvements, delivering over USD 6.5M in savings through process optimization and dynamic resource allocation. Led key regional & global initiatives, incl. a CPO forecast-accuracy improvement project across 31+ countries, strengthening financial governance and operational effectiveness in the department.

Acted as the Finance Business Partner for Global Clinical Development & Medical Affairs, supervising a USD 630M global Development expense budget and a finance team in Switzerland and the US Directing all end-to-end development finance processes (planning, forecasting, financial variance analysis, executive reporting),. Driving global accounting harmonization for commercial drug supply, and ensuring full financial compliance and transparent reporting across all CD&MA therapeutic areas (excl. Oncology).

Acted as the Finance Business Partner for Global Development BU Ophthalmic, supervising a USD 58M global Development expense budget. Led the end-to-end development finance processes such as planning, forecasting, financial variance analysis, executive reporting across all global line functions. Acting as the primary finance counterpart for external partners (Genentech, QLT) and representing Development Finance on the Joint Development Committee (JDC).

Acted as the Finance Business Partner for Global Development BU Ophthalmic with full P&L accountability for the CE & EEMEA region supervising a USD 69.5M sales budget and a 24-member finance organization. Act as Novartis Finance representative in key governance roles incl. Ophthalmic Joint Venture Board, JDC and licensing agreements generating USD 1.2M in annual royalties.

Acted as the Finance Business Partner for Global BU overseeing a USD 28M marketing budget and USD 1.037B revenue forecast Built the SAP cost center/IO infrastructure supporting strategic partnerships and BD&L initiatives, including the Novartis–WHO malaria agreement and evaluations with global organizations

Supported Divisional Finance BPAs in Group / Corporate Finance with ad hoc analysis for Shareholder meetings, Country and Cross Divisional Reviews. Part of cross divisional project aiming ot align charter of accounts across the Novartis Divisions